解决艾滋病毒中的心脏代谢挑战:最佳管理的见解,影响和最佳实践-叙述性审查
Nadine Mugisha1,2, Laura Ghanem1,3, Omar A I Komi1,4
1Oli Health Magazine Organization, Research and Education Kigali Rwanda.
Health science reports
|April 21, 2025
概括
高活性抗逆转录病毒疗法 (HAART) 增加了艾滋病毒感染者的生存率,但没有预防心脏代谢并发症. 早期发现和管理这些风险对于改善长期健康结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 传染性疾病 传染性疾病
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 高活性抗逆转录病毒疗法 (HAART) 显著改善了人类免疫缺陷病毒 (HIV) 患者的生存率.
- 尽管寿命延长,但艾滋病毒感染者面临心脏代谢并发症的更高发病率,包括心血管疾病,胰岛素耐药性,脂质失调症和脂质缩症.
- 这些并发症源于慢性炎症,免疫激活,ART相关的代谢效应和生活方式因素的复杂相互作用.
研究的目的:
- 提供对艾滋病毒和心脏代谢障碍之间的关系的细微了解.
- 探索这些并发症的临床影响.
- 为艾滋病毒感染者和心脏代谢健康挑战的人群适应最佳管理策略.
主要方法:
- 使用预先确定的搜索策略进行了系统的文献审查.
- 数据从主要的文献数据库中获取,包括PubMed,Science Direct和Embase.
- 综合了有关心脏代谢挑战和艾滋病毒之间的关联的当前文献.
主要成果:
- 艾滋病毒感染者具有患心血管疾病,胰岛素耐药性,脂质不良和脂质变的高风险.
- 建议进行常规的心脏代谢风险评估,预防和查.
- 优化抗逆转录病毒疗法 (ART) 方案和实施生活方式干预措施 (饮食,运动) 是减少负面健康结果的关键.
结论:
- 通过定期查,早期发现心血管风险因素对于及时干预至关重要.
- 医疗保健提供者,研究人员和决策者之间的合作对于应对不断变化的挑战至关重要.
- 持续的研究和宣传工作将推动知识的发展,并优化艾滋病毒感染者的长期健康结果.
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


